Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomised in-practice evaluation of the influence of patient's understanding of her disease and therapy on persistence and compliance to adjuvant therapy for post-menopausal hormone-sensitive early breast cancer.

Next Previous
X
Search
Trial Profile

A randomised in-practice evaluation of the influence of patient's understanding of her disease and therapy on persistence and compliance to adjuvant therapy for post-menopausal hormone-sensitive early breast cancer.

Status: Discontinued
Phase of Trial: Phase IV

Latest Information Update: 19 Apr 2013

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Anastrozole (Primary)
  • Indications Early breast cancer
  • Focus Therapeutic Use
  • Acronyms PACT
  • Sponsors AstraZeneca

    • Most Recent Events

    • 06 Jun 2012 New source identified and integrated (German Clinical Trials Register: DRKS00003872).
    • 22 Jun 2011 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
    • 07 Jun 2011 Twelve and 24-month follow-up results presented at the 47th Annual Meeting of the American Society of Clinical Oncology.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top